Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2956339 | 0.98 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2466395 | 0.98 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL6442487 | 0.98 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL1767658 | 0.98 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2706203 | 0.98 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL29489145 | 0.98 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL1460547 | 0.96 | CA4 (0.43) | CA4CPT2ACLY | |
| SCHEMBL966173 | 0.96 | CA4 (0.43) | CA4CPT2ACLY | |
| SCHEMBL965645 | 0.96 | CA4 (0.48) | CA4CPT2ACLY | |
| Zinc Ion SCHEMBL2315207 | 0.96 | CA4 (0.43) | CA4CPT2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053773-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AUHUI TONGOO PHARMACEUTICAL TECH CO LTD (CN) | 2026-02-26 | — | — | US | claimed |
| US-20260042814-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2026-02-12 | — | — | US | claimed |
| EP-3784774-B1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | US HEALTH (US) | 2025-11-19 | — | — | EP | claimed |
| US-12415845-B2 | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-09-16 | — | — | US | claimed |
| CN-118726256-A | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-10-01 | — | — | CN | claimed |
| WO-2024046340-A9 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 安徽汤谷医药科技有限公司 | 2024-08-15 | — | — | WO | claimed |
| CN-112262212-B | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-07-12 | — | — | CN | claimed |
| CN-118320360-A | Easily-decomposed high-performance fire extinguishing coolant for aerosol fire extinguishing agent | 湖北及安盾消防科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| WO-2024046340-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 安徽汤谷医药科技有限公司 | 2024-03-07 | — | — | WO | claimed |
| CN-117343601-A | Preparation method of friction-resistant anti-decoloration electrochemical aluminum color layer coating | 江苏众立生包装科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| US-20060240074-A1 | Novel triple mineral salts of (-)-hydroxycitric acid and processes for preparing the same | LAILA IMPEX (IN) | 2006-10-26 | — | — | US | claimed |
| US-20060210650-A1 | Supplemental dietary composition for promoting weight loss | HALO FORMULATIONS LTD. (CA) | 2006-09-21 | — | — | US | claimed |
| WO-2006063443-A2 | SUPPLEMENT DIETARY COMPOSITION FOR PROMOTING WEIGHT LOSS | LEAN BALANCE FORMULATIONS LTD. (CA) | 2006-06-22 | — | — | WO | claimed |
| EP-1657984-A1 | READY-TO-DRINK FORMULATION CONTAINING AN ACTIVE INGREDIENT | Shannon Minerals Ltd. (IE) | 2006-05-24 | — | — | EP | claimed |
| WO-2005085164-A1 | NOVEL TRIPLE MINERAL SALTS OF (-)-HYDROXYCITRIC ACID AND PROCESSES FOR PREPARING THE SAME | GOKARAJU GANGA RAJU (IN) | 2005-09-15 | — | — | WO | claimed |
| WO-2005009147-A1 | READY-TO-DRINK FORMULATION CONTAINING AN ACTIVE INGREDIENT | SHANNON MINERALS LTD. (IE) | 2005-02-03 | — | — | WO | claimed |
| WO-2003092730-A1 | HYDROXYCITRIC ACID SALT COMPOSITION AND METHOD OF MAKING | UNIBAR CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030207942-A1 | Hydroxycitric acid salt composition and method of making | UNIBAR CORPORATION (US) | 2003-11-06 | — | — | US | claimed |
| US-5783603-A | INCREASE FAT METABOLISM | SABINSA CORPORATION (US) | 1998-07-21 | — | — | US | claimed |
| WO-1996036585-A1 | A NEW PROCESS FOR THE PRODUCTION OF POTASSIUM HYDROXY CITRIC ACID, AND COMPOSITIONS CONTAINING THE POTASSIUM HYDROXY CITRIC ACID | SABINSA CORPORATION (US) | 1996-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060240074-A1 | Novel triple mineral salts of (-)-hydroxycitric acid and processes for preparing the same | HCAR1, SLC5A6, CA6 | CA4 123/4885CPT2 1751/4885ACLY 130/4885 |
| US-20260053773-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLS, ATP6V1B1, PYGL | CA4 68/4885CPT2 269/4885ACLY 211/4885 |
| US-20260042814-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | NFATC1, SLC9A1, NHERF1 | CA4 1156/4885CPT2 648/4885ACLY 3175/4885 |
| US-20030207942-A1 | Hydroxycitric acid salt composition and method of making | HCAR1, HCAR2, HAAO | CA4 153/4885CPT2 845/4885ACLY 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.